Lesaffre Human Care Launches Lynside® Pro GI+ Probiotic Yeast for People Suffering from Intestinal Discomfort and Irritable Bowel Syndrome
September 22, 2010
Milwaukee, WI – Lesaffre Human Care has broadened its range of nutritional yeasts with the introduction of Lynside® Pro GI+, a probiotic yeast intended for people suffering from intestinal discomfort such as that caused by Irritable Bowel Syndrome (IBS).
Lynside Pro GI+ is a Saccharomyces cerevisiae yeast that acts to target intestinal discomfort. It was selected by Lesaffre among 6,000 proprietary strains and has been registered with the French National Collection of Microorganism Cultures. A patent application covering many different capacities has been filed.
Several preclinical trials and one clinical trial have been conducted successfully with Lynside® Pro GI+, and two additional clinical trials will be completed by the end of 2011. A European article 13.5 functional health claim has been submitted to European Food and Safety Authority (EFSA). The proposed health claim is: "Noticeably reduces digestive discomfort after four weeks of consumption."
Since 2005, preclinical trials (in-vitro, ex-vivo and in-vivo) have been ongoing with Lynside® Pro GI+. These trials have demonstrated that the strain survives transit through the gastrointestinal tract, has anti-inflammatory properties and reduces the perception of intestinal pain.
One of the preclinical trials on the anti-inflammatory potential of several non-pathogenic yeast strains was published in the World Journal of Gastroenterology, May 2010.
Two presentations were given at the American Digestive Disease Week convention in May 2010. The first presented the results of Lynside® Pro GI+ effects on the modulation of bowel pain in a preclinical study and the second presented positive effects of Lynside® Pro GI+ on the adhesion of enteroinvasive Escherichia coli in patients with Crohn’s disease.
In 2008, a placebo-controlled, double-blind randomized clinical trial was conducted by international specialist of inflammatory bowel diseases, Professor Pierre Desreumaux of the University of Lille in France. In the clinical trial, 200 volunteers with symptoms of IBS took 500 mg/day of Lynside Pro GI+ (8x109 cfu/g) for eight weeks.
The study showed that intestinal pain and discomfort are greatly relieved after four weeks of taking Lynside® Pro GI+ (significant difference between placebo and active product) and Lynside® Pro GI+ had favorable effects on the bowel disorders caused by IBS such as abdominal and intestinal pain and discomfort, bloating, flatulence and constipation.